{"id":"https://openalex.org/W2891356992","doi":"https://doi.org/10.1016/j.euf.2018.08.022","title":"ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer","display_name":"ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer","publication_year":2018,"publication_date":"2018-09-05","ids":{"openalex":"https://openalex.org/W2891356992","doi":"https://doi.org/10.1016/j.euf.2018.08.022","mag":"2891356992","pmid":"https://pubmed.ncbi.nlm.nih.gov/30194031"},"language":"en","primary_location":{"id":"doi:10.1016/j.euf.2018.08.022","doi":"https://doi.org/10.1016/j.euf.2018.08.022","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.euf.2018.08.022","pdf_url":null,"source":{"id":"https://openalex.org/S2764909046","display_name":"European Urology Focus","issn_l":"2405-4569","issn":["2405-4569"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Urology Focus","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.euf.2018.08.022","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011563007","display_name":"Katriina Johanna Peltola","orcid":"https://orcid.org/0000-0002-3007-193X","observed_orcids":["https://orcid.org/0000-0002-3007-193X"]},"institutions":[{"id":"https://openalex.org/I2800394112","display_name":"Helsinki University Hospital","ror":"https://ror.org/02e8hzf44","country_code":"FI","type":"healthcare","lineage":["https://openalex.org/I2800394112","https://openalex.org/I4210166427"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Katriina J. Peltola","raw_affiliation_strings":["Helsinki University Hospital, Comprehensive Cancer Centre, Helsinki, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Helsinki University Hospital, Comprehensive Cancer Centre, Helsinki, Finland","institution_ids":["https://openalex.org/I2800394112"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006874570","display_name":"Petri Bono","orcid":"https://orcid.org/0000-0003-3963-0416","observed_orcids":["https://orcid.org/0000-0003-3963-0416"]},"institutions":[{"id":"https://openalex.org/I2800394112","display_name":"Helsinki University Hospital","ror":"https://ror.org/02e8hzf44","country_code":"FI","type":"healthcare","lineage":["https://openalex.org/I2800394112","https://openalex.org/I4210166427"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Petri Bono","raw_affiliation_strings":["Helsinki University Hospital, Comprehensive Cancer Centre, Helsinki, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Helsinki University Hospital, Comprehensive Cancer Centre, Helsinki, Finland","institution_ids":["https://openalex.org/I2800394112"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Robert Hugh Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150388","display_name":"Velindre Cancer Centre","ror":"https://ror.org/049sr1d03","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799279586","https://openalex.org/I4210150388"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert Hugh Jones","raw_affiliation_strings":["Velindre Cancer Centre, Cardiff, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Velindre Cancer Centre, Cardiff, UK","institution_ids":["https://openalex.org/I4210150388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000159955","display_name":"Egils Vjaters","orcid":"https://orcid.org/0000-0003-0054-3745","observed_orcids":["https://orcid.org/0000-0003-0054-3745"]},"institutions":[{"id":"https://openalex.org/I4210099352","display_name":"Pauls Stradi\u0146\u0161 Clinical University Hospital","ror":"https://ror.org/00h1aq868","country_code":"LV","type":"healthcare","lineage":["https://openalex.org/I4210099352"]}],"countries":["LV"],"is_corresponding":false,"raw_author_name":"Egils Vjaters","raw_affiliation_strings":["P. Stradins Clinical University Hospital, Riga, Latvia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"P. Stradins Clinical University Hospital, Riga, Latvia","institution_ids":["https://openalex.org/I4210099352"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087914789","display_name":"Pirjo Nyk\u00e4nen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Pirjo Nyk\u00e4nen","raw_affiliation_strings":["Orion Corporation Orion Pharma, Espoo, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037984757","display_name":"Annamari Vuorela","orcid":"https://orcid.org/0000-0002-2830-2313","observed_orcids":["https://orcid.org/0000-0002-2830-2313"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Annamari Vuorela","raw_affiliation_strings":["Orion Corporation Orion Pharma, Espoo, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082795809","display_name":"Riikka Oksala","orcid":"https://orcid.org/0000-0001-6256-562X","observed_orcids":["https://orcid.org/0000-0001-6256-562X"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Riikka Oksala","raw_affiliation_strings":["Orion Corporation Orion Pharma, Espoo, Finland"],"raw_orcid":"https://orcid.org/0000-0001-6256-562X","affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007512767","display_name":"Pasi Pohjanjousi","orcid":"https://orcid.org/0009-0004-0689-2764","observed_orcids":["https://orcid.org/0009-0004-0689-2764"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Pasi Pohjanjousi","raw_affiliation_strings":["Orion Corporation Orion Pharma, Espoo, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021509081","display_name":"Mika V. J. Mustonen","orcid":"https://orcid.org/0000-0002-7899-0564","observed_orcids":["https://orcid.org/0000-0002-7899-0564"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":true,"raw_author_name":"Mika V.J. Mustonen","raw_affiliation_strings":["Orion Corporation Orion Pharma, Espoo, Finland. Electronic address: mika.mustonen@orionpharma.com","Orion Corporation Orion Pharma, Espoo, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland. Electronic address: mika.mustonen@orionpharma.com","institution_ids":["https://openalex.org/I4210118237"]},{"raw_affiliation_string":"Orion Corporation Orion Pharma, Espoo, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007779528","display_name":"Karim S. Fizazi","orcid":"https://orcid.org/0000-0002-6068-9474","observed_orcids":["https://orcid.org/0000-0002-6068-9474"]},"institutions":[{"id":"https://openalex.org/I102197404","display_name":"Universit\u00e9 Paris-Sud","ror":"https://ror.org/028rypz17","country_code":"FR","type":"education","lineage":["https://openalex.org/I102197404","https://openalex.org/I277688954"]},{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Karim Fizazi","raw_affiliation_strings":["Institut Gustave-Roussy, University of Paris Sud, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave-Roussy, University of Paris Sud, Villejuif, France","institution_ids":["https://openalex.org/I102197404","https://openalex.org/I2801843802"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090082356","display_name":"Christophe Massard","orcid":"https://orcid.org/0000-0001-5505-0564","observed_orcids":["https://orcid.org/0000-0001-5505-0564"]},"institutions":[{"id":"https://openalex.org/I102197404","display_name":"Universit\u00e9 Paris-Sud","ror":"https://ror.org/028rypz17","country_code":"FR","type":"education","lineage":["https://openalex.org/I102197404","https://openalex.org/I277688954"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I277688954","display_name":"Universit\u00e9 Paris-Saclay","ror":"https://ror.org/03xjwb503","country_code":"FR","type":"education","lineage":["https://openalex.org/I277688954"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christophe Massard","raw_affiliation_strings":["Drug Development Department (DITEP), Inserm Unit U981, Universit\u00e9 Paris Saclay, Universit\u00e9 Paris-Sud, Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Development Department (DITEP), Inserm Unit U981, Universit\u00e9 Paris Saclay, Universit\u00e9 Paris-Sud, Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I102197404","https://openalex.org/I154526488","https://openalex.org/I277688954"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5021509081"],"corresponding_institution_ids":["https://openalex.org/I4210118237"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":0.3022,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.47002924,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"6","issue":"1","first_page":"63","last_page":"70"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11146","display_name":"Hormonal and reproductive studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9039999842643738},{"id":"https://openalex.org/keywords/cyp17-inhibition","display_name":"CYP17 inhibition","score":0.9380000233650208},{"id":"https://openalex.org/keywords/androgen-receptor-inhibition","display_name":"androgen receptor inhibition","score":0.9070000052452087},{"id":"https://openalex.org/keywords/dual-inhibitors","display_name":"dual inhibitors","score":0.7049999833106995},{"id":"https://openalex.org/keywords/androgen-deprivation-therapy","display_name":"androgen deprivation therapy","score":0.5199999809265137},{"id":"https://openalex.org/keywords/testosterone","display_name":"testosterone","score":0.5490000247955322},{"id":"https://openalex.org/keywords/prostate-specific-antigen","display_name":"prostate-specific antigen","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9070000052452087},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8669999837875366},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5270000100135803},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.7609999775886536},{"id":"https://openalex.org/keywords/prednisone","display_name":"prednisone","score":0.5479999780654907},{"id":"https://openalex.org/keywords/antitumour-activity","display_name":"antitumour activity","score":0.8190000057220459},{"id":"https://openalex.org/keywords/oral-therapy","display_name":"oral therapy","score":0.33899998664855957}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.931914746761322},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.8540571331977844},{"id":"https://openalex.org/C142716871","wikidata":"https://www.wikidata.org/wiki/Q408305","display_name":"CYP17A1","level":3,"score":0.6887921094894409},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.6201245784759521},{"id":"https://openalex.org/C2779256933","wikidata":"https://www.wikidata.org/wiki/Q58929","display_name":"Castration","level":3,"score":0.6198634505271912},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.5512055158615112},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5165135264396667},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4827289283275604},{"id":"https://openalex.org/C2780980858","wikidata":"https://www.wikidata.org/wiki/Q110022","display_name":"Dual (grammatical number)","level":2,"score":0.44464483857154846},{"id":"https://openalex.org/C2781440318","wikidata":"https://www.wikidata.org/wiki/Q1806228","display_name":"Orchiectomy","level":2,"score":0.4276338517665863},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.39297980070114136},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.31112122535705566},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.06978890299797058},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C124952713","wikidata":"https://www.wikidata.org/wiki/Q8242","display_name":"Literature","level":1,"score":0.0},{"id":"https://openalex.org/C142362112","wikidata":"https://www.wikidata.org/wiki/Q735","display_name":"Art","level":0,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013254","descriptor_name":"Steroid 17-alpha-Hydroxylase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059002","descriptor_name":"Androgen Receptor Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D059002","descriptor_name":"Androgen Receptor Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D064129","descriptor_name":"Prostatic Neoplasms, Castration-Resistant","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.euf.2018.08.022","doi":"https://doi.org/10.1016/j.euf.2018.08.022","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.euf.2018.08.022","pdf_url":null,"source":{"id":"https://openalex.org/S2764909046","display_name":"European Urology Focus","issn_l":"2405-4569","issn":["2405-4569"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Urology Focus","raw_type":"journal-article"},{"id":"pmid:30194031","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30194031","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European urology focus","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:https://orca.cardiff.ac.uk:120397","doi":null,"is_oa":false,"landing_page_url":"https://orca.cardiff.ac.uk/id/eprint/120397/1/JONES%2C%20Robert%20-%20ODM-204%2C%20a%20novel%20dual%20inhibitor%20of%20CYP17A1%20and%20androgen%20receptor%20Early.pdf","pdf_url":"https://orca.cardiff.ac.uk/id/eprint/120397/1/JONES%2C%20Robert%20-%20ODM-204%2C%20a%20novel%20dual%20inhibitor%20of%20CYP17A1%20and%20androgen%20receptor%20Early.pdf","source":{"id":"https://openalex.org/S4306401195","display_name":"ORCA Online Research @Cardiff (Cardiff University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79510175","host_organization_name":"Cardiff University","host_organization_lineage":["https://openalex.org/I79510175"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"pmh:oai:helda.helsinki.fi:10138/310589","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10138/310589","pdf_url":null,"source":{"id":"https://openalex.org/S4210213322","display_name":"Ty\u00f6v\u00e4entutkimus Vuosikirja","issn_l":"0784-1272","issn":["0784-1272","1459-7780"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":["ddh","jufo-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1016/j.euf.2018.08.022","doi":"https://doi.org/10.1016/j.euf.2018.08.022","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.euf.2018.08.022","pdf_url":null,"source":{"id":"https://openalex.org/S2764909046","display_name":"European Urology Focus","issn_l":"2405-4569","issn":["2405-4569"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Urology Focus","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307771","display_name":"Bayer","ror":"https://ror.org/04hmn8g73"},{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320309470","display_name":"Meso Scale Diagnostics","ror":"https://ror.org/05jgy0m16"},{"id":"https://openalex.org/F4320314481","display_name":"Ipsen Biopharmaceuticals","ror":"https://ror.org/03bzkqg41"},{"id":"https://openalex.org/F4320319981","display_name":"Physicians' Services Incorporated Foundation","ror":"https://ror.org/0385yzn06"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1904433804","https://openalex.org/W1969172484","https://openalex.org/W1972753189","https://openalex.org/W1985734141","https://openalex.org/W1996138419","https://openalex.org/W2014751188","https://openalex.org/W2022635468","https://openalex.org/W2051025382","https://openalex.org/W2081365151","https://openalex.org/W2109143299","https://openalex.org/W2110534364","https://openalex.org/W2112730174","https://openalex.org/W2134825260","https://openalex.org/W2138684882","https://openalex.org/W2143295509","https://openalex.org/W2404460725","https://openalex.org/W2664930764","https://openalex.org/W2742917991","https://openalex.org/W2793841534"],"related_works":["https://openalex.org/W2471058813","https://openalex.org/W2398096659","https://openalex.org/W2793841534","https://openalex.org/W2593343403","https://openalex.org/W2515346734","https://openalex.org/W1935981533","https://openalex.org/W2587844368","https://openalex.org/W2999276922","https://openalex.org/W4390227891","https://openalex.org/W1902440608"],"abstract_inverted_index":{"BACKGROUND:":[0],"Most":[1],"prostate":[2,7,256],"cancer":[3,8,257],"patients":[4,64],"develop":[5],"castration-resistant":[6,255],"(CRPC)":[9],"after":[10,149],"androgen":[11,21,105,171,252],"deprivation":[12],"therapy":[13],"treatment.":[14],"CRPC":[15,67],"growth":[16],"is":[17],"mediated":[18],"mostly":[19],"by":[20,25,30],"receptor":[22],"signalling":[23],"driven":[24],"primary":[26],"androgens":[27],"synthesised":[28],"largely":[29],"the":[31,37,139,157,174,202,220,228,240,251,279,282],"CYP17A1":[32,103,249],"enzyme.":[33],"OBJECTIVE:":[34],"To":[35],"evaluate":[36],"safety":[38,241],"profile":[39],"and":[40,56,85,104,117,124,187,212,250,267,274],"dose-limiting":[41],"toxicities":[42],"of":[43,76,102,126,222,227,242,248,281],"ODM-204.":[44],"DESIGN,":[45],"SETTING,":[46],"AND":[47,109,131],"PARTICIPANTS:":[48],"In":[49],"this":[50],"open,":[51],"uncontrolled,":[52],"nonrandomised,":[53],"multicentre,":[54],"tolerability":[55],"pharmacokinetic":[57,225],"first-in-man":[58],"phase":[59],"I":[60],"dose":[61,78,136,159],"escalation":[62],"study,":[63],"with":[65,90,153,167],"metastatic":[66],"were":[68,122,165,207],"randomised":[69],"to":[70,201,263],"receive":[71],"ODM-204":[72,112,168,189,196,259],"in":[73,162,182,209,219,254],"sequential":[74],"cohorts":[75],"five":[77],"levels":[79,121,164],"(ie,":[80],"50,":[81],"100,":[82],"200,":[83],"300,":[84],"500mg":[86],"twice":[87],"daily)":[88],"concomitantly":[89],"prednisone.":[91],"INTERVENTION:":[92],"ODM-204,":[93,243],"a":[94,179,193,244],"novel,":[95],"orally":[96],"administered,":[97],"investigational,":[98],"nonsteroidal":[99],"dual":[100,246],"inhibitor":[101,247],"receptor.":[106],"OUTCOME":[107],"MEASUREMENTS":[108],"STATISTICAL":[110],"ANALYSIS:":[111],"plasma":[113],"concentrations,":[114],"serum":[115,272],"testosterone,":[116],"prostate-specific":[118,275],"antigen":[119,276],"(PSA)":[120],"evaluated":[123,204],"imaging":[125],"lesions":[127],"was":[128,144,197,261],"performed.":[129],"RESULTS":[130],"LIMITATIONS:":[132],")":[133],"values":[134],"increased":[135],"dependently":[137],"until":[138],"300mg":[140],"dose.":[141,205],"The":[142,224],"AUC":[143],"lower":[145],"on":[146],"day":[147,154],"8":[148],"repeated":[150],"dosing":[151],"compared":[152],"1":[155],"from":[156],"200mg":[158],"upwards.":[160],"Decreases":[161],"testosterone":[163,211,273],"seen":[166],"treatment":[169,190,221,260],"confirming":[170],"deprivation.":[172],"Of":[173],"patients,":[175],"13%":[176],"also":[177,269],"demonstrated":[178],">50%":[180],"decrease":[181],"PSA":[183,213],"at":[184,239],"week":[185],"12":[186],"continued":[188],"for":[191],"over":[192],"year.":[194],"CONCLUSIONS:":[195],"well":[198,265],"tolerated":[199],"up":[200],"highest":[203],"There":[206],"decreases":[208],"both":[210,271],"levels,":[214,277],"suggesting":[215],"preliminary":[216],"antitumour":[217],"activity":[218],"CRPC.":[223],"properties":[226,280],"molecule,":[229],"however,":[230],"prevent":[231,284],"further":[232,285],"development.":[233,286],"PATIENT":[234],"SUMMARY:":[235],"This":[236],"study":[237],"looked":[238],"novel":[245],"receptor,":[253],"patients.":[258],"found":[262],"be":[264],"tolerated,":[266],"it":[268],"reduced":[270],"but":[278],"molecule":[283]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-09-27T00:00:00"}